-
Something wrong with this record ?
Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice
Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B.
Language English Country Germany
NLK
PubMed Central
from 1982
ProQuest Central
from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-03-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-03-01 to 1 year ago
- MeSH
- Doxorubicin analogs & derivatives therapeutic use MeSH
- Financing, Organized MeSH
- Immunoglobulins therapeutic use MeSH
- Immune Tolerance MeSH
- Polymethacrylic Acids therapeutic use MeSH
- Humans MeSH
- Lymphoma, T-Cell drug therapy immunology prevention & control MeSH
- Melanoma, Experimental drug therapy immunology metabolism MeSH
- Survival Rate MeSH
- Mice, Inbred C57BL MeSH
- Mice, Nude MeSH
- Mice MeSH
- Tumor Cells, Cultured transplantation MeSH
- Skin Neoplasms drug therapy immunology metabolism MeSH
- Drug Carriers MeSH
- Antibiotics, Antineoplastic therapeutic use MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
Linkage of doxorubicin (Dox) to a water-soluble synthetic N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) eliminates most of the systemic toxicity of the free drug. In EL-4 lymphoma-bearing C57BL/6 mice, a complete regression of pre-established tumours has been achieved upon treatment with Dox-PHPMA-HuIg conjugate. The treatment was effective using a range of regimens and dosages, ranging from 62.5 to 100% cured mice treated with a single dose of 10-20 mg of Dox eq./kg, respectively. Fractionated dosages producing lower levels of the conjugate for a prolonged time period had substantial curative capacity as well. The cured mice developed anti-tumour protection as they rejected subsequently re-transplanted original tumour. The proportion of tumour-protected mice inversely reflected the effectiveness of the primary treatment. The treatment protocol leading to 50% of cured mice produced only protected mice, while no mice treated with early treatment regimen (i.e. starting on day 1 after tumour transplantation) rejected the re-transplanted tumour. Exposure of the host to the cancer cells was a prerequisite for developing protection. The anti-tumour memory was long lasting and specific against the original tumour, as the cured mice did not reject another syngeneic tumour, melanoma B16-F10. The immunity was transferable to naive recipients in in vivo neutralization assay by spleen cells or CD8(+) lymphocytes derived from cured animals. We propose an effective treatment strategy which eradicates tumours without harming the protective immune anti-cancer responses.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09004027
- 003
- CZ-PrNML
- 005
- 20130214234800.0
- 008
- 091130s2007 gw e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Šírová, Milada $7 xx0127158
- 245 10
- $a Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice / $c Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B.
- 314 __
- $a Division of Immunology and Gnotobiology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. sirova@biomed.cas.cz
- 520 9_
- $a Linkage of doxorubicin (Dox) to a water-soluble synthetic N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) eliminates most of the systemic toxicity of the free drug. In EL-4 lymphoma-bearing C57BL/6 mice, a complete regression of pre-established tumours has been achieved upon treatment with Dox-PHPMA-HuIg conjugate. The treatment was effective using a range of regimens and dosages, ranging from 62.5 to 100% cured mice treated with a single dose of 10-20 mg of Dox eq./kg, respectively. Fractionated dosages producing lower levels of the conjugate for a prolonged time period had substantial curative capacity as well. The cured mice developed anti-tumour protection as they rejected subsequently re-transplanted original tumour. The proportion of tumour-protected mice inversely reflected the effectiveness of the primary treatment. The treatment protocol leading to 50% of cured mice produced only protected mice, while no mice treated with early treatment regimen (i.e. starting on day 1 after tumour transplantation) rejected the re-transplanted tumour. Exposure of the host to the cancer cells was a prerequisite for developing protection. The anti-tumour memory was long lasting and specific against the original tumour, as the cured mice did not reject another syngeneic tumour, melanoma B16-F10. The immunity was transferable to naive recipients in in vivo neutralization assay by spleen cells or CD8(+) lymphocytes derived from cured animals. We propose an effective treatment strategy which eradicates tumours without harming the protective immune anti-cancer responses.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorová antibiotika $x terapeutické užití $7 D000903
- 650 _2
- $a doxorubicin $x analogy a deriváty $x terapeutické užití $7 D004317
- 650 _2
- $a nosiče léků $7 D004337
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologická tolerance $7 D007108
- 650 _2
- $a imunoglobuliny $x terapeutické užití $7 D007136
- 650 _2
- $a lymfom T-buněčný $x farmakoterapie $x imunologie $x prevence a kontrola $7 D016399
- 650 _2
- $a melanom experimentální $x farmakoterapie $x imunologie $x metabolismus $7 D008546
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši nahé $7 D008819
- 650 _2
- $a kyseliny polymethakrylové $x terapeutické užití $7 D011109
- 650 _2
- $a nádory kůže $x farmakoterapie $x imunologie $x metabolismus $7 D012878
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádorové buňky kultivované $x transplantace $7 D014407
- 700 1_
- $a Strohalm, Jiří $7 xx0109134
- 700 1_
- $a Šubr, Vladimír, $d 1957- $7 xx0088449
- 700 1_
- $a Plocová, Daniela $7 xx0109133
- 700 1_
- $a Rossmann, Pavel, $d 1933- $7 jk01102749
- 700 1_
- $a Mrkvan, Tomáš $7 xx0062385
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877
- 700 1_
- $a Říhová, Blanka, $d 1942- $7 jo20000073671
- 773 0_
- $w MED00001041 $t Cancer immunology and immunotherapy $g Roč. 56, č. 1 (2007), s. 35-47 $x 0340-7004
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20091123115031 $b ABA008
- 991 __
- $a 20130214234949 $b ABA008
- 999 __
- $a ok $b bmc $g 699845 $s 562257
- BAS __
- $a 3
- BMC __
- $a 2007 $b 56 $c 1 $d 35-47 $i 0340-7004 $m Cancer immunology and immunotherapy $x MED00001041
- LZP __
- $a 2009-B3/dkme